American Journal Of Pathology · 2013 · 130 citations · 46 references
Life SciencesNeurobiologyNeuroscienceCell SignalingCellular NeuroscienceMolecular NeuroscienceAngiogenesisBlood-brain Barrier BiologyGrowth Factor SignalingNeuroprotectionNeurotrophic FactorsAngiogenic Factor ExpressionBlood - Retinal BarrierNeuroprotective SignalingRetinal Ganglion Cell NeuroprotectionVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
Vascular endothelial growth factor (VEGF) A is generated as two isoform families by alternative RNA splicing, represented by VEGF-A165a and VEGF-A165b. These isoforms have opposing actions on vascular permeability, angiogenesis, and vasodilatation. The proangiogenic VEGF-A165a isoform is neuroprotective in hippocampal, dorsal root ganglia, and retinal neurons, but its propermeability, vasodilatatory, and angiogenic properties limit its therapeutic usefulness. In contrast, a neuroprotective effect of endogenous VEGF-A165b on neurons would be advantageous for neurodegenerative pathologies. Endogenous expression of human and rat VEGF-A165b was detected in hippocampal and cortical neurons. VEGF-A165b formed a significant proportion of total VEGF-A in rat brain. Recombinant human VEGF-A165b exerted neuroprotective effects in response to multiple insults, including glutamatergic excitotoxicity in hippocampal neurons, chemotherapy-induced cytotoxicity of dorsal root ganglion neurons, and retinal ganglion cells (RGCs) in rat retinal ischemia-reperfusion injury in vivo. Neuroprotection was dependent on VEGFR2 and MEK1/2 activation but not on p38 or phosphatidylinositol 3–kinase activation. Recombinant human VEGF-A165b is a neuroprotective agent that effectively protects both peripheral and central neurons in vivo and in vitro through VEGFR2, MEK1/2, and inhibition of caspase-3 induction. VEGF-A165b may be therapeutically useful for pathologies that involve neuronal damage, including hippocampal neurodegeneration, glaucoma diabetic retinopathy, and peripheral neuropathy. The endogenous nature of VEGF-A165b expression suggests that non–isoform-specific inhibition of VEGF-A (for antiangiogenic reasons) may be damaging to retinal and sensory neurons. Vascular endothelial growth factor (VEGF) A is generated as two isoform families by alternative RNA splicing, represented by VEGF-A165a and VEGF-A165b. These isoforms have opposing actions on vascular permeability, angiogenesis, and vasodilatation. The proangiogenic VEGF-A165a isoform is neuroprotective in hippocampal, dorsal root ganglia, and retinal neurons, but its propermeability, vasodilatatory, and angiogenic properties limit its therapeutic usefulness. In contrast, a neuroprotective effect of endogenous VEGF-A165b on neurons would be advantageous for neurodegenerative pathologies. Endogenous expression of human and rat VEGF-A165b was detected in hippocampal and cortical neurons. VEGF-A165b formed a significant proportion of total VEGF-A in rat brain. Recombinant human VEGF-A165b exerted neuroprotective effects in response to multiple insults, including glutamatergic excitotoxicity in hippocampal neurons, chemotherapy-induced cytotoxicity of dorsal root ganglion neurons, and retinal ganglion cells (RGCs) in rat retinal ischemia-reperfusion injury in vivo. Neuroprotection was dependent on VEGFR2 and MEK1/2 activation but not on p38 or phosphatidylinositol 3–kinase activation. Recombinant human VEGF-A165b is a neuroprotective agent that effectively protects both peripheral and central neurons in vivo and in vitro through VEGFR2, MEK1/2, and inhibition of caspase-3 induction. VEGF-A165b may be therapeutically useful for pathologies that involve neuronal damage, including hippocampal neurodegeneration, glaucoma diabetic retinopathy, and peripheral neuropathy. The endogenous nature of VEGF-A165b expression suggests that non–isoform-specific inhibition of VEGF-A (for antiangiogenic reasons) may be damaging to retinal and sensory neurons. Vascular endothelial growth factor (VEGF) A, originally described as a potent vascular permeability and growth factor for endothelial cells, is up-regulated in the brain during stroke and ischemic episodes1Kovacs Z. Ikezaki K. Samoto K. Inamura T. Fukui M. VEGF and flt: expression time kinetics in rat brain infarct.Stroke. 1996; 27: 1865-1872Crossref PubMed Scopus (271) Google Scholar and has been linked with many neuronal diseases. The most widely studied isoform of VEGF-A, VEGF-A165a, is up-regulated in hypoxia, induces increased vascular permeability in neuronal vasculature, and can stimulate angiogenesis after ischemic episodes. The resulting edema and hyperemia can be damaging, but VEGF-A165a has also been found to have direct anticytotoxic effects on neurons, raising the possibility that it may act as an endogenous neuroprotective agent in neurodegenerative pathologies. VEGF-A exerts neurotrophic (survival) and neurotropic (neurogenesis and axon outgrowth) actions, which, although initially thought to be a function of increased angiogenesis and perfusion after neuronal injury,2Hobson M.I. Green C.J. Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy.J Anat. 2000; 197: 591-605Crossref PubMed Google Scholar are now appreciated as direct effects of VEGF-A on neurons. The vegfa gene encodes numerous products by differential splicing, but not all isoforms exert the same effects.3Harper S.J. Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?.Nat Rev Cancer. 2008; 8: 880-887Crossref PubMed Scopus (407) Google Scholar Alternative splicing of exon 8 leads to two functionally distinct families: the proangiogenic VEGF-Axxxa family and the counteracting VEGF-Axxxb family.4Bates D.O. Cui T.G. Doughty J.M. Winkler M. Sugiono M. Shields J.D. Peat D. Gillatt D. Harper S.J. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.Cancer Res. 2002; 62: 4123-4131PubMed Google Scholar, 5Woolard J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar VEGF-A165b prevents the VEGF-A165a effects on increased vascular permeability, blood vessel growth, and vasodilatation.4Bates D.O. Cui T.G. Doughty J.M. Winkler M. Sugiono M. Shields J.D. Peat D. Gillatt D. Harper S.J. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.Cancer Res. 2002; 62: 4123-4131PubMed Google Scholar, 5Woolard J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, 6Qiu Y. Ferguson J. Oltean S. Neal C.R. Kaura A. Bevan H. Wood E. Sage L.M. Lanati S. Nowak D.G. Salmon A.H. Bates D. Harper S.J. Overexpression of VEGF165b in podocytes reduces glomerular permeability.J Am Soc Nephrol. 2010; 21: 1498-1509Crossref PubMed Scopus (36) Google Scholar, 7Cebe Suarez S. Pieren M. Cariolato L. Arn S. Hoffmann U. Bogucki A. Manlius C. Wood J. Ballmer-Hofer K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.Cell Mol Life Sci. 2006; 63: 2067-2077Crossref PubMed Scopus (170) Google Scholar The therapeutic potential of VEGF-A and anti–VEGF-A treatments are now widely recognized, and effective anti–VEGF-A treatments are available in ophthalmology8Rosenfeld P.J. Brown D.M. Heier J.S. Boyer D.S. Kaiser P.K. Chung C.Y. Kim R.Y. Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4929) Google Scholar and oncology.9Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. Berlin J. Baron A. Griffing S. Holmgren E. Ferrara N. Fyfe G. Rogers B. Ross R. Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med. 2004; 350: PubMed Scopus Google Scholar The that VEGF-A is in neuronal diabetic and E. D. as a angiogenic factor, now in 2004; PubMed Scopus Google a for the of VEGF-A as a therapeutic agent in neurodegenerative is by M. G. M. Vascular endothelial growth factor has neurotrophic and cell and cell in the peripheral PubMed Google Scholar the of the VEGF-Axxxb family of VEGF-A isoforms in to for the that VEGF-A splicing are not functionally S.J. Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?.Nat Rev Cancer. 2008; 8: 880-887Crossref PubMed Scopus (407) Google Scholar and to of the proangiogenic isoform family may have effects in and in The neuroprotective of the exon 8 isoforms VEGF-Axxxb VEGF-Axxxb isoforms not the vascular effects with VEGF-Axxxa as a in permeability or J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, Harper S.J. Bates D.O. The anti-angiogenic VEGF isoform VEGF165b through VEGF in 2006; PubMed Scopus Google Scholar The of potential effects may VEGF-Axxxb isoforms as therapeutic in neurodegenerative diseases. the that VEGF-A165b is neuroprotective for central and peripheral neurons. found that VEGF-A165b is in central neurons and is neuroprotective in vitro and in vivo. that VEGF-A165b may to be a therapeutic agent in neurodegenerative effects and or protein and Recombinant human VEGF-A165b was by or of retinal and cytotoxicity was plus available VEGF-A protein was in or H.S. Qiu Y. Foster J. A. Harper S.J. Bates D.O. The anti-angiogenic family of VEGF isoforms in human 2008; Scopus Google Scholar or was in by available a and a for isoforms or two for total as J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar VEGF-A and VEGF-A165b detected available The VEGF-A165b the of the VEGF-Axxxb J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, A.H. Qiu Y. Bevan H.S. Perrin S. C. Harper S.J. Bates D.O. VEGF an antiangiogenic VEGF-A and in colorectal of and antiangiogenic VEGF-A isoforms has for J Cancer. 2008; PubMed Scopus Google Scholar in the of endogenous VEGF isoforms in have been S. M. J. M. C. anti-angiogenic VEGF isoforms a PubMed Scopus Google Scholar in that the of to can of to the VEGF165b and These are also found the is that The of human and rat the not human or rat of a was the same and the same a the was for in the of as a the the same and a the was for in the of the the same and by the or the of in with the and with of hippocampal neuronal excitotoxicity was in of hippocampal neurons as C.R. B. A. R. D. as a neuroprotective factor to the A. 2004; PubMed Scopus Google Scholar on in and cells in neuronal growth plus with and and with of to growth of on of to for in the of VEGF-A165b and or the mechanism of with VEGF-A165b in the of VEGF-A and signaling and was by a to a The cells and and to a cells with with of dorsal root ganglion neuronal was in of rat neurons. was and and and the cells and in with A total of of was to cells neurons for with to of to of or with for with agent or with for of cell and on a with for of cells and by or in and to for the of caspase-3 of by with or The of neurons by a to In VEGFR2 expression was detected a VEGFR2 The was by and to for sensory neuronal cells W. R. N. M. A. and of a dorsal root ganglion sensory neuronal PubMed Scopus Google for protein after VEGF-A165b of the protein available cells with that to with for and with to the for was in with plus by and was in for and in and in in and in in for and on a The effect of VEGF-A165b on in rat neurons was as S. A. R. D. of the gene reduces the of sensory neurons and A. 2000; PubMed Scopus Google Scholar neurons with or VEGF-A165b for and the of A total of to to the effect of VEGF-A165b on after with a described M. J.M. M. ganglion cell after of and a in vivo Sci. 1996; Google Scholar, T. K. C. W. J. M. of ischemic in the rat a and Sci. 2008; PubMed Scopus Google Scholar in was and in to for and is in and is for K. K. T. A of retinal ganglion cells the in the Res. PubMed Scopus Google Scholar to of an of of VEGF-A165b in of in the same of and after to retinal as M. J.M. M. ganglion cell after of and a in vivo Sci. 1996; Google Scholar, T. K. C. W. J. M. of ischemic in the rat a and Sci. 2008; PubMed Scopus Google Scholar and the was and and was for with that the to The of the retinal blood was direct during the of retinal was as after of after for caspase-3 to the of ischemic and after ischemia-reperfusion injury in rat Sci. Google Scholar cells in the retinal ganglion and The with after and the of neurons by an to nerve injury on was as J.S. F. K. and of the nerve a of PubMed Scopus Google Scholar with the to in was in the of the of the nerve was a and the was with in the and that an in the of the VEGF-A165b or the same the of the in the the same after and after by of and with and for factor of and are in the or of and all are with or a or in of human brain that VEGF-A165b was in the human hippocampal all and and the with neurons also in neurons through the The of a the same or of the with VEGF165b significant and with not the protein was rat and VEGF-Axxxb and total VEGF-A by VEGF-Axxxb and of total VEGF-A in the and and VEGF-Axxxa splice are to be the of VEGF-Axxxb splice as neuroprotective in hippocampal neurons, central neurons that are to hippocampal neuronal in a A and and was potent has been described as a potent hippocampal neuroprotective C.R. B. A. R. D. as a neuroprotective factor to the A. 2004; PubMed Scopus Google Scholar the VEGF-A165b cell was the same as cells, inhibition of VEGF-A165b is a VEGF-A also as in H. Harper S.J. Bates D.O. L. Vascular endothelial growth factor is a in vitro for VEGF to of binding and of Res. 2008; PubMed Scopus Google Scholar In hippocampal neurons, the neuroprotective of VEGF-A165b was dependent on VEGFR2 activation as has been described for H. M. A. K. H. N. M. Vascular endothelial growth factor hippocampal neurons J. Google Scholar The of cell in the of VEGF-A165b was by the both and J.M. G. E. R. S. J. F. J. H. T. E. J. C. D. A. H. F. K. A. G. M. J. G. F. a and potent of vascular endothelial growth factor vascular endothelial growth and growth after Res. 2000; Google and C.E. J. Harper S.J. Bates D.O. a of vascular endothelial growth 2002; PubMed Scopus Google but was by has for Harper S.J. Bates D.O. The anti-angiogenic VEGF isoform VEGF165b through VEGF in 2006; PubMed Scopus Google neurons in VEGFR2 by VEGF-A165b was dependent on signaling of the VEGFR2 through the as it was also by the as is also the for E. L. T. The VEGFR2 and to in neuronal PubMed Scopus (36) Google Scholar Neuroprotection was not by of p38 by or phosphatidylinositol 3–kinase with A and of neurons with VEGF-A165b increased was by the effect of inhibition on VEGF-A165b of hippocampal neurons to the cell after with in the of or in or plus VEGF-A165b with or or In the of plus VEGF-A165b plus neurons The of total was neurons with the MEK1/2 plus VEGF-A165b with VEGF-A165b and p38 inhibition effect on the exerted by VEGF-A165b. are of of plus of cell in plus plus with of cell in plus VEGF-A165b and The of detected by was increased in neurons with with of by VEGF165b in neurons with VEGF-A165b also exerted a neuroprotective on retinal neurons in vivo In retinal a in of was ischemic neuronal was by VEGF-A165b was to for caspase-3 and ischemic significant retinal neuronal through as by of neurons and and caspase-3 The in neuronal was by VEGF-A165b A, and with the and in both and cells and VEGF-A165a has been found to be injury by a of to D. E. M. J. F. S. J. A. S. R. L. R. H.S. H. S. S. T. N. L. M. C. L. R. W. C. D. VEGF is a of in and and protects ischemic PubMed Scopus Google Scholar was to central neurons or also peripheral neurons, neurons The of VEGF-A165b increased the of during to but not the of neurons in and a neurotrophic A total of VEGF-A165b an in caspase-3 in neurons by of with the with or increased the of neurons with neurons, and VEGF-A165b A and VEGF165b was as an endogenous neuroprotective factor for rat cells with an to VEGF165b with or the In the of and of VEGF and effect or In contrast, with in a significant in the proportion of cells after with a also the cell is to and can be as a of cell in also in significant in cell was by the of of neurons for VEGFR2 expression on the cell the the neuroprotective response to with VEGFR2 or during and for and caspase-3 with of or with a significant in the of cells with and and with human VEGF-A165b the of cells with and effect was by with the VEGFR2 a for cells with growth factor the cell its by VEGF165b an to VEGF165b was through VEGFR2, cells with and VEGF165b in the of as a or the VEGFR2 VEGFR2 by not neuronal or the it the of VEGF-A165b be a of peripheral nerve injury that in activation of in neurons, as R. D. of a in 2008; PubMed Scopus Google Scholar and A and with the of neuronal expression in with after VEGF-A165a, the splice isoform VEGF-A165b is neuroprotective for central and peripheral neurons, in vitro and in and neuroprotective effect through VEGFR2 and MEK1/2 activation. In to its neuroprotective VEGF-A165b also has neurotrophic actions on neurons. VEGF-A165a has been found to a key in neuronal in to its actions on the vasculature, of hypoxia, and B. L. E. H. D. K. J. M. S. G. M. H. T. L. N. H. R. F. C. F. W. J.M. D. of the in the vascular endothelial growth factor PubMed Scopus Google Scholar of VEGF-A expression to the of in D. E. M. J. F. S. J. A. S. R. L. R. H.S. H. S. S. T. N. L. M. C. L. R. W. C. D. VEGF is a of in and and protects ischemic PubMed Scopus Google Scholar VEGF-A and its are also in central and peripheral cells, as and cells, also to neuronal and E. D. as a angiogenic factor, now in 2004; PubMed Scopus Google Scholar, of vascular endothelial growth and therapeutic PubMed Scopus Google Scholar In the central VEGF-A165a protects hippocampal, and neurons numerous D.A. Vascular endothelial growth factor cells by Mol 2000; PubMed Google Scholar, D.A. Vascular endothelial growth direct neuroprotective effect in in vitro A. 2000; PubMed Scopus Google Scholar, A. H. D. J.S. Vascular endothelial growth factor is up-regulated after and protects neuronal in 2008; PubMed Scopus Google Scholar, J.M. N. A. J.M. effects of vascular endothelial growth factor on cortical and cortical Google Scholar through VEGFR2, signaling through activation of multiple including and of vascular endothelial growth and therapeutic PubMed Scopus Google Scholar effects on cells, as cells, and are through E. D. as a angiogenic factor, now in 2004; PubMed Scopus Google Scholar In contrast, that by VEGF-A165b in hippocampal neurons, although also through VEGFR2, MEK1/2 but not or p38 The for and VEGF-Axxxa binding J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, 7Cebe Suarez S. Pieren M. Cariolato L. Arn S. Hoffmann U. Bogucki A. Manlius C. Wood J. Ballmer-Hofer K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.Cell Mol Life Sci. 2006; 63: 2067-2077Crossref PubMed Scopus (170) Google Scholar, H. K. L. S. A. D. Ballmer-Hofer K. L. M. L. in of activation of and endothelial cell 2008; PubMed Scopus Google Scholar but the VEGF-Axxxb isoforms are not of the VEGFR2 binding of VEGF-A165b in differential of H. Harper S.J. Bates D.O. L. Vascular endothelial growth factor is a in vitro for VEGF to of binding and of Res. 2008; PubMed Scopus Google Scholar and neurotrophic actions by VEGF-A165a may also involve the VEGF neuropilin-1 of vascular endothelial growth and therapeutic PubMed Scopus Google VEGF-A165b to and not binding to and H. Harper S.J. Bates D.O. L. Vascular endothelial growth factor is a in vitro for VEGF to of binding and of Res. 2008; PubMed Scopus Google Scholar the that the differential VEGFR2 and MEK1/2 activation exerted by VEGF-A165b is to central and peripheral neurons, on both central and peripheral sensory neurons that the neuroprotective mechanism of VEGF-A165b is that to VEGF-A165a in that through of caspase-3 of vascular endothelial growth and therapeutic PubMed Scopus Google Scholar In the endogenous VEGF-A is a factor for ischemia-reperfusion K. L. J. W. N. J. S.J. Vascular endothelial growth is a factor for retinal neurons and a during the response to ischemic J PubMed Scopus Google Scholar and neuronal the for binding the binding H. K. L. S. A. D. Ballmer-Hofer K. L. M. L. in of activation of and endothelial cell 2008; PubMed Scopus Google also exerted neuroprotective that VEGF-A165b can both and cell through VEGFR2 activation. The of neuronal is in diabetic as and the of ganglion cells to in M. B. A. The of retinal ganglion cell in Res. PubMed Scopus Google Scholar have found that VEGF-A165b is for endothelial and retinal J. Bevan H.S. N. C. M. J. Harper S.J. Bates D.O. VEGF-A165b is and antiangiogenic in the Sci. 2010; PubMed Scopus Google Scholar it is antiangiogenic in the J. C. S. Qiu Y. A. S. Harper S.J. Bates D.O. Recombinant human VEGF165b Sci. 2010; PubMed Scopus Google Scholar of the to neurons in the by VEGF-A165b would also be a in therapeutic for diabetic and In hippocampal and peripheral sensory neurons, VEGF-A165b also enhances that VEGF-A165b exerts neurotrophic also through In peripheral sensory and neurons, VEGF-A165a enhances neuronal in M. G. M. Vascular endothelial growth factor has neurotrophic and cell and cell in the peripheral PubMed Google Scholar, of vascular endothelial growth and therapeutic PubMed Scopus Google Scholar, G. effects of neurotrophic factor and vascular endothelial growth factor in of and 2010; PubMed Scopus Google Scholar VEGFR2 is in both the central and peripheral but in neuronal VEGF-A M. M. expression of VEGF and its in peripheral PubMed Scopus Google Scholar, T. A. T. S. R. M. R. E. of neuronal by A. PubMed Scopus Google Scholar These that VEGF-A isoforms exert actions on neurons through neuroprotective and neurotrophic effects may be that VEGF-A165b is a VEGF-A splice variant found in central and peripheral neurons, it is to exert VEGF-A165b is also in human and J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, R.O. Qiu Y. A.H. A. H. Harper S.J. Bates D.O. of the inhibitory isoforms of in J Cancer. PubMed Scopus Google Scholar it also exert effects on peripheral sensory neurons. VEGF-A165b has inhibitory effects on J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, A.H. Qiu Y. Bevan H.S. Perrin S. C. Harper S.J. Bates D.O. VEGF an antiangiogenic VEGF-A and in colorectal of and antiangiogenic VEGF-A isoforms has for J Cancer. 2008; PubMed Scopus Google Scholar, E. Waine E. H. Y. W. J. Sugiono M. Gillatt D. E. Bates D. Harper S. The endogenous anti-angiogenic VEGF VEGF165b human growth in J Cancer. 2008; PubMed Scopus Google Scholar but not in angiogenesis, or J. Wang W.Y. Bevan H.S. Qiu Y. Morbidelli L. Pritchard-Jones R.O. Cui T.G. Sugiono M. Waine E. Perrin R. Foster R. Digby-Bell J. Shields J.D. Whittles C.E. Mushens R.E. Gillatt D.A. Ziche M. Harper S.J. Bates D.O. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.Cancer Res. 2004; 64: 7822-7835Crossref PubMed Scopus (397) Google Scholar, 6Qiu Y. Ferguson J. Oltean S. Neal C.R. Kaura A. Bevan H. Wood E. Sage L.M. Lanati S. Nowak D.G. Salmon A.H. Bates D. Harper S.J. Overexpression of VEGF165b in podocytes reduces glomerular permeability.J Am Soc Nephrol. 2010; 21: 1498-1509Crossref PubMed Scopus (36) Google Scholar, A. Y. C. D. S. Ballmer-Hofer K. S. L. Bates D.O. Harper S.J. Recombinant human VEGF165b protein is an effective agent in J Cancer. 2008; PubMed Scopus Google Scholar that VEGF-A165b has neuroprotective effects to to VEGF-A165a, on central and peripheral neurons. is key in the of many and anti–VEGF-A have in H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. Berlin J. Baron A. Griffing S. Holmgren E. Ferrara N. Fyfe G. Rogers B. Ross R. Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med. 2004; 350: PubMed Scopus Google Scholar and P.J. Brown D.M. Heier J.S. Boyer D.S. Kaiser P.K. Chung C.Y. Kim R.Y. Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4929) Google Scholar of VEGF-A in neurodegenerative M. G. M. Vascular endothelial growth factor has neurotrophic and cell and cell in the peripheral PubMed Google Scholar, D. E. M. J. F. S. J. A. S. R. L. R. H.S. H. S. S. T. N. L. M. C. L. R. W. C. D. VEGF is a of in and and protects ischemic PubMed Scopus Google Scholar, G. M. C. M. M. J. A.H. J.M. effect of VEGF gene on ischemic peripheral Med. 2000; PubMed Scopus Google Scholar, K. R. C. M. A.H. J.M. of diabetic by VEGF gene PubMed Scopus Google Scholar, T. T. K. M. T. Y. H. H. effects of VEGF on a rat of Res. PubMed Scopus Google Scholar VEGF-A is now for of neuronal for in diabetic A.H. A. J. Rogers A. D. R. D. Vascular endothelial growth factor gene for diabetic a PubMed Scopus Google Scholar effective in has to be the of in to the potential of and cell function in VEGF-A has been found to have E. D. as a angiogenic factor, now in 2004; PubMed Scopus Google Scholar and R. K. Gillatt D.A. Bates D.O. Harper S.J. that vascular endothelial growth factor may act as an factor on human J PubMed Scopus Google Scholar that VEGF-Axxxb can exert neuroprotective and neurotropic effects with VEGF-Axxxa both hippocampal neurons in and retinal neurons in and the that for in VEGF-A has been not the function of the or cell that VEGF-A165b may be an alternative therapeutic agent in neurodegenerative with vascular
46
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text
Medicine, Ophthalmology, Surgery +12
J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations
Medicine, Oncology, Pharmacology +16
Mariann Sondell, Göran Lundborg, Martin Kanje · Journal of Neuroscience · 1999 · 749 citations · Full text